Evidence map›Paper›PMID 42327300›Full record

ArticlebioRxiv : the preprint server for biology2026

Robust semi-supervised scRNA-seq integration from virtual adversarial learning.

Chuan He, Paraskevas Filippidis, Jian Xing, Steven Kleinstein, Leying Guan

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chuan HeDepartment of Biostatistics, Yale School of Public Health, New Haven, 06511, CT, US.ORCID 0000-0002-6412-450X
Paraskevas FilippidisDepartment of Pathology, Yale School of Medicine, New Haven, 06511, CT, US.
Jian XingDepartment of Pathology, Yale School of Medicine, New Haven, 06511, CT, US.
Steven KleinsteinDepartment of Pathology, Yale School of Medicine, New Haven, 06511, CT, US.
Leying GuanDepartment of Biostatistics, Yale School of Public Health, New Haven, 06511, CT, US.

Funding

HIPC Data Coordinating CenterU01AI167892 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Steven H. Kleinstein, Bjoern Peters · 2022 to 2026
$18.7M
NIAID NIH HHS U01 AI167892
6 · The paper itself

Abstract

Single-cell RNA sequencing integration methods that rely solely on transcriptomic data often struggle to preserve fine-grained distinctions between closely related cell subtypes. As a result, cell populations that are separable in the raw data may become over-mixed after integration, reducing biological resolution and interpretability. Incorporating marker gene information can potentially address these issues; however, the variability and complexity of available marker sets limit their effective application. To address this, we introduce scCRAFT+, a semi-supervised integration model that innovatively incorporates marker gene information through Virtual Adversarial Training (VAT). By jointly optimizing marker-derived supervision and transcriptome-wide representations, VAT enforces local prediction smoothness among transcriptionally similar cells, improving robustness to noisy marker annotations while enhancing both integration quality and cell type auto-annotation. This targeted approach significantly enhances annotation accuracy and robustness, particularly when faced with incomplete or incorrect marker gene sets. Benchmarking shows that scCRAFT+ achieves consistently stronger performance than current unsupervised and supervised integration approaches, resulting in improved integration quality and biologically meaningful sub-cell type auto-annotations.

Identifiers

PMID42327300
PMCPMC13278090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.